Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1622 1634 1641 1644
This examiner grants 50% of resolved cases
Maher M. Haddad is an examiner in Art Unit 1622 within Tech Center 1600. With 1061 resolved cases, the examiner has a record for analysis. The 1061 resolved cases provide a perspective on how this examiner handles various patent applications. The allowance rate of 50.4 percent indicates the frequency at which applications reaching a final disposition are granted. This rate suggests an approach to examination where practitioners must present arguments to overcome rejections.
The data reveals an interview lift of 53.9 percent. This metric suggests that engaging in a direct dialogue with the examiner is a strategy for moving toward an allowance compared to the baseline allowance rate of 50.4 percent. For those applications that do reach a grant, the median days to allowance is 1120. This timeline helps practitioners set expectations for the duration of the prosecution process when navigating this examiner's requirements.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18279191 | HIGH POTENCY T CELL RECEPTORS FOR IMMUNOTHERAPY | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 18551679 | METHODS OF TREATING CANCER IN IMMUNOSUPPRESSED OR IMMUNOCOMPROMISED PATIENTS BY ADMINISTERING A PD-1 INHIBITOR | Non-Final OA | Sanofi Biotechnology |
| 17609757 | COMPOSITIONS AND METHODS FOR TREATING CANCER | Non-Final OA | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS |
| 18971607 | LOW-DOSE TOCILIZUMAB FOR THE TREATMENT OR PREVENTION OF SICKLE CELL CRISIS | Non-Final OA | The University of Chicago |
| 18035054 | METHODS FOR ADMINISTERING A BCMAXCD3 BINDING MOLECULE | Final Rejection | AMGEN INC. |
| 18700535 | MOLECULES THAT BIND TO CD276 POLYPEPTIDES | Non-Final OA | University of Pittsburgh of the Commonwealth System of Higher Education |
| 18491703 | ANTI-FOLATE RECEPTOR CONJUGATE THERAPY FOR CANCER TREATMENT | Non-Final OA | Fred Hutchinson Cancer Center |
| 18265217 | MULTISPECIFIC ANTIGEN BINDING PROTEIN | Final Rejection | JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. |
| 16208294 | FORMULATION FOR ANTI-ALPHA4BETA7 ANTIBODY AND METHODS OF TREATMENT | Non-Final OA | Takeda Pharmaceutical Company Limited |
| 18031731 | ANTIBODY-DRUG CONJUGATE AND APPLICATION THEREOF | Final Rejection | KEYMED BIOSCIENCES CO., LTD |
| 18277521 | HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST CD22 | Non-Final OA | The United States of America,as represented by the Secretary,Department of Health and Human Services |
| 18134844 | NUCLEIC ACIDS ENCODING HUMAN ANTIBODIES TO SIALYL-LEWIS A | Final Rejection | BioNTech SE |
| 16753159 | BISPECIFIC ANTIBODY | Final Rejection | ONO PHARMACEUTICAL CO., LTD. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy